ADC Landscape
Pfizer
CD33 · Acute myeloid leukemia
ApprovedAntibody–Drug Conjugates
Target
CD33
Payload
Calicheamicin
Payload class
DNA-damaging
Linker
Hydrolyzable hydrazone
Indication
Acute myeloid leukemia
Phase
Approved
Overview
The original ADC (first approved 2000), withdrawn, then re-approved at a lower fractionated dose. The cautionary tale that taught the field about therapeutic index.
Technology
Pfizer works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.